Literature DB >> 10568763

Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women.

A Hemauer1, A Gigler, K Searle, K Beckenlehner, U Raab, K Broliden, H Wolf, G Enders, S Modrow.   

Abstract

Parvovirus B19 is the causative agent of erythema infectiosum in children, but the virus is associated with an increasing range of different diseases. These include acute and chronic arthritis, hydrops fetalis in pregnant women, aplastic anemia, and thrombocytopenia. The host's immune response is directed against the viral structural proteins VP1 and VP2. This study investigated the presence of IgG against the viral nonstructural protein NS1 using Western blot. Serum panels from healthy individuals, B19-infected pregnant women, and various disease groups were tested. The disease groups included patients with symptoms that may be linked to parvovirus B19 infection. The results showed that IgG against the NS1 protein was present in 22% of healthy individuals with past B19 infection. In cases of persistent or prolonged B19 infections, the prevalence of NS1-specific antibodies was as high as 80%. It is concluded that NS1-specific IgG may be used as an indicator of chronic or more severe courses of parvovirus B19 infections. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10568763     DOI: 10.1002/(sici)1096-9071(200001)60:1<48::aid-jmv9>3.0.co;2-e

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

Review 2.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

3.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity.

Authors:  Simone Dorsch; Gerhard Liebisch; Bärbel Kaufmann; Philipp von Landenberg; Jörg H Hoffmann; Wolfgang Drobnik; Susanne Modrow
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Prevalence of parvovirus B19-specific antibodies and of viral DNA in patients with endogenous uveitis.

Authors:  Carsten Heinz; Annelie Plentz; Dirk Bauer; Arnd Heiligenhaus; Susanne Modrow
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

Review 6.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  Long term follow up of serostatus after maternofetal parvovirus B19 infection.

Authors:  J Dembinski; A M Eis-Hübinger; J Maar; R Schild; P Bartmann
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 8.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

9.  Detection of human parvovirus B19 nonstrutural protein DNA by nested-polymerase chain reaction in gravida serum and pregnant tissues.

Authors:  Ting Shen; Yongmei Huang; Fuyuan Qiao; Zengqing Li; Haiyi Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.